|
1
|
31
|
Female
|
1
|
Ph-ALL
|
Refractory
|
56.0%
|
2
|
No
|
|
2
|
23
|
Female
|
1
|
Ph+ALL*(T315I mutation)
|
Relapse
|
38.6%
|
2
|
No
|
|
3
|
50
|
Male
|
0
|
Ph-ALL
|
Refractory
|
3.0%
|
2
|
No
|
|
4
|
18
|
Male
|
0
|
Ph-ALL
|
Relapse
|
30.5%
|
2
|
No
|
|
5
|
44
|
Male
|
0
|
Ph-ALL
|
Refractory
|
24.5%
|
2
|
No
|
|
6
|
16
|
Male
|
0
|
Ph-ALL (IKZF1 deletion, NRAS mutation)
|
Refractory
|
26.0%
|
3
|
No
|
|
7
|
10
|
Male
|
0
|
Ph-ALL (E2A-PBX1 rearrangement)
|
Relapse
|
4.5%
|
2
|
No
|
|
8
|
16
|
Male
|
0
|
Ph+ALL (T315I mutation)
|
Relapse
|
83.5%
|
2
|
No
|
|
9
|
24
|
Male
|
1
|
Ph-ALL
|
Relapse
|
40.5%
|
2
|
No
|
|
10
|
9
|
Male
|
0
|
Ph-ALL (IgH rearrangements)
|
Refractory
|
40.5%
|
2
|
No
|
|
11
|
7
|
Male
|
0
|
Ph-ALL
|
Relapse
|
7.5%
|
2
|
No
|
|
12
|
9
|
Female
|
0
|
Ph-ALL (ETV6-RUNX1 rearrangement)
|
Relapse
|
10.0%
|
2
|
No
|
|
13
|
19
|
Male
|
0
|
Ph-like ALL (EBF1-PDGFRB rearrangement, IKZF1 deletion)
|
Relapse
|
75.0%
|
2
|
Yes
|
|
14
|
14
|
Female
|
0
|
Ph-ALL
|
Refractory
|
32.5%
|
3
|
No
|
|
15
|
18
|
Male
|
0
|
Ph-like ALL (PAX5-JAK2 rearrangement, TP53 deletion)
|
Relapse
|
73.5%
|
1
|
No
|
|
16
|
43
|
Female
|
1
|
Ph-ALL
|
Refractory
|
60.5%
|
2
|
No
|
|
17
|
11
|
Female
|
0
|
Ph-ALL
|
Refractory
|
5.0%
|
2
|
No
|
|
18
|
3
|
Female
|
0
|
Ph-ALL (TP53 mutation, IKZF1 deletion)
|
Refractory
|
6.0%
|
5
|
No
|
|
19
|
52
|
Female
|
0
|
Ph-ALL
|
Refractory
|
96.0%
|
2
|
No
|
|
20
|
40
|
Male
|
0
|
Ph-ALL (IKZF1 deletion)
|
Refractory
|
64.5%
|
2
|
Yes
|
